About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Ohio | 763 Studies

Clinical Trials LymphomaOhio

Lymphoma Clinical Trials in Ohio

Find 763 clinical trials for lymphoma near Ohio. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Ohio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 41-60 of 763 trials

CompletedMK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaThis phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or…NCT01231919·Birmingham, Alabama and 24 others

PreviousPage 3 of 39Next

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingEvolut™ EXPAND TAVR II Pivotal TrialObtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.NCT05149755·Birmingham, Alabama and 93 others

CompletedFLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).NCT02448381·Birmingham, Alabama and 32 others

RecruitingA Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibThe master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies…NCT06876649·Jacksonville, Florida and 37 others

CompletedEfficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisThe primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or…NCT03120949·Mesa, Arizona and 238 others

CompletedEscalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaThe purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic…NCT01351935·Huntsville, Alabama and 12 others

Active not recruitingAntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaThe purpose of this study is to determine if it is possible to treat your cancer with a new type of T cell-based immunotherapy (therapy that uses your immune system to treat the…NCT03434769·St Louis, Missouri and 1 other

RecruitingStudy of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALLThe goal of this clinical trial is to learn if the combination of drugs Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone (IoVeX) are safe to treat relapsed B-cell Acute…NCT06863259·Cincinnati, Ohio

TerminatedEfficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasThe primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated…NCT01732926·Huntsville, Alabama and 143 others

CompletedSWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin LymphomaRATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.NCT01000558·Mobile, Alabama and 202 others

CompletedFirst-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasThe ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas.NCT03188965·Duarte, California and 28 others

Active not recruitingNKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersThis is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting…NCT05020678·Denver, Colorado and 5 others

TerminatedGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaThis phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with…NCT01088763·Palo Alto, California and 11 others

CompletedStudy Evaluating CMC-544 In B-Cell Non-Hodgkin's LymphomaTo determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).NCT00073749·Birmingham, Alabama and 21 others

RecruitingA Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory…NCT06393738·New Haven, Connecticut and 20 others

CompletedA Study of Enzastaurin in Participants With Follicular LymphomaTo evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in participants with Follicular Lymphoma (FL).NCT00475644·Casa Grande, Arizona and 22 others

CompletedPh I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLThe purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of…NCT00546793·Savannah, Georgia and 4 others

RecruitingA Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaThis feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride…NCT04139304·Miami, Florida and 8 others

TerminatedEverolimus and Bortezomib in Treating Patients With Relapsed or Refractory LymphomaRATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.NCT00671112·Cleveland, Ohio

RecruitingA Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaThe primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major…NCT05645107·Bullhead City, Arizona and 61 others

Other Conditions in Ohio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia